BigHat's design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of optimizing antibodies and other therapeutic proteins.
Under the collaboration, BigHat and Merck will collaborate to optimize up to three proteins by leveraging BigHat's platform to synthesize, express, purify, and characterize molecules.
The teams have initiated work on the first program and are looking forward to using the power of the complementary skills sets within each research team to generate high-quality lead antibodies.
BigHat Biosciences is designing safer, more effective antibody therapies for patients using machine learning and synthetic biology.
BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies.
They apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from TODAY's most challenging diseases.
BigHat is a series B biotech outside San Francisco with a team-oriented, inclusive, and family-friendly culture.
BigHat's pipeline of wholly-owned and partnered therapeutic programs span many disparate indications with high unmet need, such as cancer, inflammation, and infectious disease.
BigHat has raised over USD 100m from top investors, including Section 32, a16z, and 8VC.
Tango Therapeutics granted FDA clearance of IND for TNG462
Innate Pharma receives HSR clearance for expansion of collaboration with Sanofi on NK Cell Engagers
ImmPACT Bio USA's IMPT-314 IND application receives US FDA approval
US FDA Approves Brenzavvy for the Treatment of Adults with Type 2 Diabetes
KBI Biopharma Enters Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment
Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
First Cohort Dosed in Phase 1 Clinical Study of ADX-324
Illuminare Biotechnologies doses first patient in phase one Illuminare-1 trial
Cadrenal Therapeutics' tecarfarin receives US FDA Fast Track designation